Impact of Antibody Cocktail Therapy Combined with Casirivimab and Imdevimab on Clinical Outcome for patients with COVID-19 in A Real-Life Setting: A Single Institute Analysis카시리비맙 및 임데비맙과 결합된 항체 칵테일 요법이 실제 환경에서 COVID-19 환자의 임상 결과에 미치는 영향: 단일 기관 분석Article Published on 2022-04-012022-09-12 Journal: International Journal of Infectious Diseases [Category] COVID19(2023년), SARS, 임상, 진단, [키워드] 95%CI Analysis analyzed antibody cocktail Casirivimab clinical Clinical practice clinical trial cocktail Combined COVID-19 COVID-19 pandemic death effective Factor high-risk patient hospital Hospitalization Hospitalized Imdevimab Impact initial Isolation medical intervention oxygen saturation Patient patients with COVID-19 recent reduced reducing reduction REGEN-COV risk Ronapreve SARS-CoV-2 significantly therapy with COVID-19 [DOI] 10.1016/j.ijid.2022.01.067 PMC 바로가기 [Article Type] Article
Estimated Health Outcomes and Costs of COVID-19 Prophylaxis With Monoclonal Antibodies Among Unvaccinated Household Contacts in the US미국에서 백신 접종을 하지 않은 가족 중 단클론 항체를 사용한 COVID-19 예방의 예상 건강 결과 및 비용Randomized Controlled Trial Published on 2022-04-012022-09-11 Journal: JAMA Network Open [Category] COVID19(2023년), SARS, 변종, 임상, 진단, [키워드] Administered age Casirivimab complementary confirmed COVID-19 case Contact Coverage COVID-19 COVID-19 case COVID-19 infection COVID-19 infections COVID-19 pandemic COVID-19 vaccination death deaths disrupt effective vaccine Effective vaccines eligible Estimated Ethnicity exposure to Health health system Hospitalization hospitalizations household household contact Imdevimab IMPROVE individual Infection intensity mAb mAbs monoclonal antibodies monoclonal antibody Older outcome Postexposure Prophylaxis Probability public health randomized clinical trial reduce reduce costs Sex subcutaneous injection subcutaneous injections susceptible symptomatic infection symptomatic infections threshold thresholds Transmission Vaccination Status Vaccine variant of SARS-CoV-2 [DOI] 10.1001/jamanetworkopen.2022.8632 PMC 바로가기 [Article Type] Randomized Controlled Trial
Pharmacological treatment of COVID-19: an opinion paperCOVID-19의 약리학적 치료: 의견서Review Published on 2022-04-012022-09-11 Journal: Revista española de quimioterapia : publicación [Category] COVID19(2023년), SARS, 치료제, [키워드] adalimumab Anakinra approach AZD7442 Azithromycin Banlanivimab Baricitinib BRII-196 BRII-198 canakinumab Casirivimab Certolizumab Ciganilmab Colchicine college Committee convalescent convalescent plasma COVID-19 Critical Dexamethasone drug drugs effective Efficacy English Etanercept etesevimab Evusheld Favipiravir fluvoxamine Golimumab help Hydroxychloroquine Imdevinab immune response Immunotherapy indication infliximab itolizumab Ivermectin Lemilumab Lopinavir Lopinavir/ritonavir Medicines metformin molnupiravir offer Pandemia pandemic Paxlovid PF-07321332 physician precocity prevented Ravulizumab Remdesivir Ritonavir ruxolitinib sarilumab SARS-CoV-2 Scientific Committee Sotrovimab Spanish the vaccine therapeutic Tixagevimab Tocilizumab Tofacitinib Treatment Vaccine virus Vitamin Vitamin D [DOI] 10.37201/req/158.2021 PMC 바로가기 [Article Type] Review
Successful early use of anti-SARS-CoV-2 monoclonal neutralizing antibodies in SARS-CoV-2 infected hematological patients – A Czech multicenter experienceSARS-CoV-2에 감염된 혈액학적 환자에서 항-SARS-CoV-2 단일클론 중화 항체의 성공적인 조기 사용 - 체코의 다기관 경험Multicenter Study Published on 2022-04-012022-09-12 Journal: Hematological oncology [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] administration analyzed anti-CD20 anti-SARS-CoV-2 anti-SARS-CoV-2 monoclonal neutralizing antibodies Asymptomatic asymptomatic patient bamlanivimab baseline Casirivimab Cohort Combination Course COVID-19 COVID-19 diagnosis COVID-19 mortality COVID-19 symptom Critical death diagnose diagnosed early administration early-stage COVID-19 Efficacy evaluated Final first COVID-19 symptom Follow-up General population hematological Hematological malignancy Imdevimab impair Infection leukemia leukemias lymphoma lymphomas median Mild moderate monoclonal monoclonal antibody monotherapy Mortality multicenter multicentre Neutralizing neutralizing antibody neutralizing monoclonal antibody nine occurred Patient patients plasma positive remained Result SARS-CoV-2 significantly significantly lower Spike protein survival rate therapy treated were recorded [DOI] 10.1002/hon.2974 PMC 바로가기 [Article Type] Multicenter Study
Comprehensive Treatment of Hematological Patients with SARS-CoV-2 Infection Including Anti-SARS-CoV-2 Monoclonal Antibodies: A Single-Center Experience Case SeriesAnti-SARS-CoV-2 단클론항체를 포함한 SARS-CoV-2 감염 혈액병 환자의 종합 치료: 단일 센터 경험 사례 시리즈Article Published on 2022-03-262022-09-11 Journal: Current Oncology [Category] MERS, SARS, 변종, 진단, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Administered Analysis antibody Antibody therapy B.1.1.529 B.1.617.2 bamlanivimab benefit best Cancer case sery Casirivimab clearance clinical clinical effectiveness Combination Comprehensive coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 patient delta variant Diagnosis Effectiveness exacerbated experience FIVE hematologic hematologic malignancies Hematologic malignancy Hematological malignancies high risk Hospitalization Imdevimab Including knowledge lAbel less mAbs monoclonal antibodies monoclonal antibody Mortality off-label omicron Omicron variant oxygen oxygen supplementation Patient Potential receiving reduce reduced reduction in respiratory retrospective risk SARS-CoV-2 SARS-CoV-2 clearance SARS-COV-2 infection SARS-CoV-2-infected patient Sery severe acute respiratory syndrome Coronavirus shown Sotrovimab suggested Tolerability Treatment variant [DOI] 10.3390/curroncol29040188 PMC 바로가기 [Article Type] Article
Effects of Casirivimab/Imdevimab Monoclonal Antibody Treatment among Vaccinated Patients Infected by SARS-CoV-2 Delta VariantSARS-CoV-2 Delta 변이에 감염된 백신 접종 환자에서 Casirivimab/Imdevimab 단일클론항체 치료 효과Article Published on 2022-03-212022-09-11 Journal: Viruses [Category] SARS, 변종, 진단, 치료기술, [키워드] acute respiratory syndrome Analysis B.1.617.2 Casirivimab casirivimab/imdevimab Chest Chest computed tomography clinical clinical evolution clinical manifestations Clinical presentations cocktail Computed tomography coronavirus coronavirus 2 Delta delta variant Disease progression early stage early stages Effect effective Efficacy evaluated Evolution FIVE Hospitalized Imdevimab Infection mAb mAbs monoclonal antibodies monoclonal antibody monoclonal antibody treatment Nasopharyngeal swab nasopharyngeal swabs Next-generation sequencing NGS outcomes Patient patients performed prevent disease progression real-time RT-PCR Regression respiratory Respiratory failure Safe SARS-CoV-2 Severe acute respiratory syndrome severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 submitted Symptom Symptoms thymoma Treatment Vaccine variant variants variants of concern Viral viral load reduction [DOI] 10.3390/v14030650 PMC 바로가기 [Article Type] Article
An update of antispike severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) monoclonal antibodiesReview Published on 2022-03-182023-07-02 Journal: Indian journal of pharmacology [Category] SARS, [키워드] bamlanivimab Casirivimab COVID-19 etesevimab Imdevimab monoclonal antibodies review Treatment [DOI] 10.4103/ijp.ijp_519_21 PMC 바로가기 [Article Type] Review
De novo emergence of a remdesivir resistance mutation during treatment of persistent SARS-CoV-2 infection in an immunocompromised patient: a case report면역 저하 환자에서 지속되는 SARS-CoV-2 감염 치료 중 렘데시비르 내성 돌연변이의 새로운 출현: 증례 보고Case Reports Published on 2022-03-172022-09-11 Journal: Nature Communications [Category] SARS, 변종, 유전자 메커니즘, 진단, 치료제, [키워드] absence Antiviral antiviral agent B-cell benefit Case report Casirivimab Course deficiency demonstrated experiment Imdevimab Immunocompromised Immunocompromised patient Immunocompromised patients in vitro increase in indolent limit Mutation Nsp12 patients receiving treatment produced recrudescence Remdesivir reported resistance mutations risk RNA polymerase RNA-dependent RNA polymerase SARS-CoV-2 SARS-COV-2 infection specimens Symptom therapy Treatment Viral viral shedding Whole genome sequencing [DOI] 10.1038/s41467-022-29104-y PMC 바로가기 [Article Type] Case Reports
The use of monoclonal antibody therapy in pediatric patients with COVID-19: a retrospective case seriesOriginal Research Published on 2022-03-032022-10-30 Journal: International Journal of Emergency Medicine [Category] COVID-19, [키워드] administration Admission adverse event age Analysis antibody bamlanivimab case sery Casirivimab Characteristics Community coronavirus disease COVID-19 COVID-19 infection COVID-19 symptom determine Emergency use authorization EUA follow-up period hospital Hospitalization Imdevimab incidence median Mild moderate monoclonal antibody morbidity Patient pediatric Pediatric patient Pediatric patients Primary outcome reducing required Result retrospective returned safety profile secondary outcome Symptom the patient therapy Two patient [DOI] 10.1186/s12245-022-00414-8 PMC 바로가기 [Article Type] Original Research
COVID-19 updates: NIH outpatient treatment guidelinesArticle Published on 2022-02-212023-07-08 Journal: The Medical letter on drugs and therapeutics [Category] COVID19(2023년), [키워드] bamlanivimab Casirivimab COVID-19 Efficacy etesevimab Imdevimab molnupiravir Nirmatrelvir Paxlovid REGEN-COV Remdesivir Ritonavir Sotrovimab Veklury